Cognition Therapeutics (CGTX) Free Cash Flow (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Free Cash Flow of -$5.5 million for Q1 2026, up 43.89% year-over-year from -$3.9 million in Q1 2025, and down 61.25% quarter-over-quarter from -$3.4 million in Q4 2025.
Cognition Therapeutics (CGTX) Free Cash Flow (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Free Cash Flow for 7 consecutive years, with -$5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 43.89% year-over-year to -$5.5 million; the TTM figure through Mar 2026 stood at -$20.3 million (up 34.89% YoY), while the FY2025 annual figure was -$24.6 million, up 13.66% from the prior year.
- Free Cash Flow declined to -$5.5 million in Q1 2026 per CGTX's latest filing, from -$3.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$27000.0 in Q3 2022 and bottomed at -$10.2 million in Q4 2022.
- Historically, Free Cash Flow has averaged -$5.5 million across 5 years, with a median of -$5.5 million in 2026.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 98.68% — and 2023, when it slumped 15525.93%.
- Cognition Therapeutics' Free Cash Flow stood at -$10.2 million in 2022, then surged by 46.18% to -$5.5 million in 2023, then slumped by 52.81% to -$8.4 million in 2024, then surged by 59.0% to -$3.4 million in 2025, then tumbled by 61.25% to -$5.5 million in 2026.
- Business Quant data shows CGTX's Free Cash Flow at -$5.5 million in Q1 2026, -$3.4 million in Q4 2025, and -$5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | -3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.05 Mn |
| Jun 30, 2026 | -3.05 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Dec 31, 2025 | -3.44 Mn |
| Dec 31, 2025 | -3.44 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Jun 30, 2025 | -5.62 Mn |
| Jun 30, 2025 | -5.62 Mn |
| Mar 31, 2025 | -9.88 Mn |
| Mar 31, 2025 | -9.88 Mn |
| Dec 31, 2024 | -8.38 Mn |
| Dec 31, 2024 | -8.38 Mn |
| Sep 30, 2024 | -6.85 Mn |
| Sep 30, 2024 | -6.85 Mn |
| Jun 30, 2024 | -6.00 Mn |
| Jun 30, 2024 | -6.00 Mn |
| Mar 31, 2024 | -7.24 Mn |
| Mar 31, 2024 | -7.24 Mn |